Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiplatelet therapy in 2005].

J C Wautrecht1, J Sternon

  • 1Service de Pathologie Vasculaire, Hôpital Erasme, Bruxelles.

Revue Medicale De Bruxelles
|February 4, 2005
PubMed
Summary

Atherothrombosis, a cause of ischemic events, can be managed with antiplatelet agents like aspirin. New data guides optimal use of aspirin, clopidogrel, dipyridamole, and glycoprotein IIb/IIIa antagonists for preventing vascular events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening Program of Abdominal Aortic Aneurysm.

Angiology·2019
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

Requirements for angiology/vascular medicine.

International angiology : a journal of the International Union of Angiology·2013
Same author

[Thrombocytosis in patients treated with low-molecular-weight heparin: more common than imagined?].

Journal des maladies vasculaires·2010
Same author

[New developments in antithrombotic care].

Revue medicale de Bruxelles·2009
Same author

[Varenicline: an aid to smoking cessation therapy].

Revue medicale de Bruxelles·2008

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Atherothrombosis is a significant cause of ischemic events in cerebral, coronary, and peripheral arteries.
  • Antiplatelet agents are crucial for secondary prevention in patients with established vascular disease or risk factors.

Purpose:

  • To review current data on antiplatelet agents, including aspirin, clopidogrel, dipyridamole, and glycoprotein IIb/IIIa antagonists.
  • To provide practical therapeutic recommendations in the evolving field of antiplatelet therapy.

Summary:

  • Atherothrombosis leads to serious ischemic events.
  • Antiplatelet therapy, particularly aspirin, is effective in preventing recurrent vascular events.
  • Optimal dosing of aspirin and the roles of other agents like clopidogrel require ongoing evaluation.

Impact:

  • Provides clinicians with updated information for managing patients at risk of atherothrombotic events.
  • Aims to optimize the use of antiplatelet agents for improved patient outcomes.
  • Contributes to evidence-based recommendations in antiplatelet therapy for vascular event prevention.

Related Experiment Videos